GCP
IMNM icon

GSA Capital Partners’s Immunome IMNM Stock Holding History

GSA Capital Partners’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,051
Closed -$242K – 1943
2026
Q1 		$242K Buy
+11,051
New +$246K 0.02% 1361
2025
Q4 		– Sell
-66,420
Closed -$778K – 1859
2025
Q3 		$778K Sell
66,420
-9,626
-13% -$95.8K 0.06% 565
2025
Q2 		$707K Buy
+76,046
New +$623K 0.05% 685

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

GSA Capital Partners's IMNM Position: Q2 2026 in Review

GSA Capital Partners sold out of Immunome (IMNM) in Q2 2026, closing a stake of 11,051 shares — an estimated $242K sold.

GSA Capital Partners first reported a position in IMNM in Q2 2025 and held it in 3 quarters. The position peaked at $778K in Q3 2025. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • GSA Capital Partners reported no remaining Immunome position as of Q2 2026 after selling out during the quarter.
  • GSA Capital Partners sold 11,051 Immunome shares in Q2 2026, an estimated $242K.
  • GSA Capital Partners first reported a position in Immunome in Q2 2025 and held it in 3 quarters.
  • GSA Capital Partners's Immunome position peaked at $778K in Q3 2025.
  • 202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.